{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:44:12Z","timestamp":1790099052675,"version":"4.0.1"},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are incretin-based therapies with demonstrated efficacy in glycaemic control, weight reduction and cardiovascular and renal protection. Although data in kidney transplant recipients (KTRs) remain limited, the high prevalences of overweight and obesity, post-transplant diabetes mellitus and cardiovascular disease in this population make GLP-1RAs a promising therapeutic strategy. This narrative review outlines the rationale for their use in KTRs, drawing from recent trials in non-transplant populations and emerging real-world evidence in KTRs. We summarize key clinical considerations, including patient selection, dose escalation and monitoring strategies, as well as existing retrospective and prospective studies examining safety and efficacy in the post-transplant setting. Available data suggest that GLP-1RAs are generally well tolerated, without clear evidence of increased risk for graft rejection, acute pancreatitis or interaction with immunosuppressive agents. However, gastrointestinal side effects and early discontinuation remain common, emphasizing the need for tailored counselling and dose titration. Importantly, the current evidence is constrained by small sample sizes, short follow-up and potential selection bias; these limitations lessen the certainty of safety and effectiveness estimates. Translational inferences from non-transplant trials (e.g. SELECT, FLOW, SMART) should also be made cautiously. Future studies should investigate long-term graft outcomes, changes in body composition and optimal integration with immunosuppressive regimens. A clear research agenda prioritizing graft survival, cardiovascular and kidney outcomes, quality of life, cost-effectiveness and patient-reported outcomes\u2014ideally via randomized, multicentre or registry-based pragmatic designs\u2014will be critical. As GLP-1RAs become increasingly accessible and clinically relevant, a multidisciplinary and patient-centred approach is essential to guide their safe and effective use in KTRs. This narrative review provides a framework for thoughtful clinical application and highlights areas for future investigation.<\/jats:p>","DOI":"10.1093\/ndt\/gfaf199","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T11:34:50Z","timestamp":1759145690000},"page":"625-635","source":"Crossref","is-referenced-by-count":6,"title":["GLP-1 receptor agonists for kidney transplant recipients"],"prefix":"10.1093","volume":"41","author":[{"given":"Sarah H","family":"Schmitz","sequence":"first","affiliation":[{"name":"Comprehensive Weight Control Center Weill Cornell Medicine Department of Medicine, , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6026-7135","authenticated-orcid":false,"given":"Babak J","family":"Orandi","sequence":"additional","affiliation":[{"name":"NYU Langone Department of Surgery, New York, NY ,","place":["USA"]},{"name":"NYU Langone Department of Medicine, New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"2026033111013036100_bib1","volume-title":"Obesity and overweight","author":"World Health Organization","year":"2025"},{"key":"2026033111013036100_bib2","article-title":"Health risks of overweight & obesity","author":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"key":"2026033111013036100_bib3","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.3390\/nu13124482","article-title":"Impact of obesity in kidney diseases","volume":"13","author":"Kotsis","year":"2021","journal-title":"Nutrients"},{"key":"2026033111013036100_bib4","volume-title":"Obesity and type 2 diabetes: a joint approach to halt the rise","author":"Helman","year":"2022"},{"issue":"2 Suppl 1","key":"2026033111013036100_bib5","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.ajt.2025.01.020","article-title":"OPTN\/SRTR 2023 annual data report: kidney","volume":"25","author":"Lentine","year":"2025","journal-title":"Am J Transplant"},{"key":"2026033111013036100_bib6","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/ndt\/gfad253","article-title":"Journey to kidney transplantation: patient dynamics, suspensions, transplantation and deaths in the Australian kidney transplant waitlist","volume":"39","author":"De La Mata","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026033111013036100_bib7","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1097\/SLA.0b013e318275a6cb","article-title":"The impact of recipient obesity on outcomes after renal transplantation","volume":"257","author":"Cannon","year":"2013","journal-title":"Ann Surg"},{"key":"2026033111013036100_bib8","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2026033111013036100_bib9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2337\/dsi24-0002","article-title":"Using second-generation anti-obesity medications","volume":"37","author":"Schmitz","year":"2024","journal-title":"Diabetes Spectr"},{"key":"2026033111013036100_bib10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026033111013036100_bib11","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026033111013036100_bib12","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026033111013036100_bib13","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"key":"2026033111013036100_bib14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026033111013036100_bib15","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat Med"},{"key":"2026033111013036100_bib16","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial","volume":"31","author":"Apperloo","year":"2025","journal-title":"Nat Med"},{"key":"2026033111013036100_bib17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026033111013036100_bib18","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.3390\/jcm10112497","article-title":"Obesity and post-transplant diabetes mellitus in kidney transplantation","volume":"10","author":"Martin-Moreno","year":"2021","journal-title":"J Clin Med"},{"key":"2026033111013036100_bib19","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.2337\/dc12-2441","article-title":"Glucose metabolism after renal transplantation","volume":"36","author":"Hecking","year":"2013","journal-title":"Diabetes Care"},{"key":"2026033111013036100_bib20","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.2215\/CJN.00520121","article-title":"Post-transplant cardiovascular disease","volume":"16","author":"Birdwell","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026033111013036100_bib21","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJM198310273091702","article-title":"Remission of essential hypertension after renal transplantation","volume":"309","author":"Curtis","year":"1983","journal-title":"N Engl J Med"},{"key":"2026033111013036100_bib22","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/bmj.292.6527.1041","article-title":"Hypertension in renal allograft recipients may be conveyed by cadaveric kidneys from donors with subarachnoid haemorrhage","volume":"292","author":"Strandgaard","year":"1986","journal-title":"BMJ"},{"key":"2026033111013036100_bib23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/TP.0b013e31817ef0f9","article-title":"Obesity and cardiac risk after kidney transplantation: experience at one center and comprehensive literature review","volume":"86","author":"Lentine","year":"2008","journal-title":"Transplantation"},{"key":"2026033111013036100_bib24","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/ctr.12616","article-title":"Coronary events in obese hemodialysis patients before and after renal transplantation","volume":"29","author":"De Lima","year":"2015","journal-title":"Clin Transplant"},{"key":"2026033111013036100_bib25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1600-6143.2005.01198.x","article-title":"Obesity and outcome following renal transplantation","volume":"6","author":"Gore","year":"2006","journal-title":"Am J Transplant"},{"key":"2026033111013036100_bib26","doi-asserted-by":"publisher","first-page":"e0243394","DOI":"10.1371\/journal.pone.0243394","article-title":"Risk factors associated with weight gain after kidney transplantation: a cohort study","volume":"15","author":"Forte","year":"2020","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"2026033111013036100_bib27","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/ndt\/gfab310","article-title":"Management of obesity in kidney transplant candidates and recipients: a clinical practice guideline by the DESCARTES Working Group of ERA","volume":"37","author":"Oniscu","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2026033111013036100_bib28","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1681\/ASN.0000000512","article-title":"ASN kidney health guidance on the management of obesity in persons living with kidney diseases","volume":"35","author":"Ikizler","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2026033111013036100_bib29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/ndt\/gfad258","article-title":"International consensus on post-transplantation diabetes mellitus","volume":"39","author":"Sharif","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026033111013036100_bib30","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2337\/dc15-2383","article-title":"GLP-1 restores altered insulin and glucagon secretion in posttransplantation diabetes","volume":"39","author":"Halden","year":"2016","journal-title":"Diabetes Care"},{"key":"2026033111013036100_bib31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1677\/jme.1.01655","article-title":"Pancreatic beta-cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs","volume":"34","author":"D\u2019Amico","year":"2005","journal-title":"J Mol Endocrinol"},{"key":"2026033111013036100_bib32","doi-asserted-by":"publisher","first-page":"e0168396","DOI":"10.1371\/journal.pone.0168396","article-title":"Liraglutide reduces both atherosclerosis and Kidney inflammation in moderately uremic LDLr\u2212\/\u2212 mice","volume":"11","author":"Bisgaard","year":"2016","journal-title":"PLoS One"},{"key":"2026033111013036100_bib33","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1111\/dom.14160","article-title":"Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials","volume":"22","author":"Verma","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2026033111013036100_bib34","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/S2213-8587(24)00371-1","article-title":"GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study","volume":"13","author":"Orandi","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026033111013036100_bib35","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3390\/jcm14020651","article-title":"Utilization trends of glucose-lowering medications among adult kidney transplant recipients with type 2 diabetes in the United States","volume":"14","author":"Hansrivijit","year":"2025","journal-title":"J Clin Med"},{"key":"2026033111013036100_bib36","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.2337\/dc13-1066","article-title":"Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series","volume":"36","author":"Pinelli","year":"2013","journal-title":"Diabetes Care"},{"key":"2026033111013036100_bib37","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1016\/j.transproceed.2018.03.087","article-title":"Management of diabetes mellitus with glucagonlike peptide-1 agonist liraglutide in renal transplant recipients: a retrospective study","volume":"50","author":"Liou","year":"2018","journal-title":"Transplant Proc"},{"key":"2026033111013036100_bib38","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/dom.13619","article-title":"Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients","volume":"21","author":"Singh","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2026033111013036100_bib39","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/dom.13964","article-title":"Comparison of the glucagon-like-peptide-1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: a retrospective study","volume":"22","author":"Singh","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2026033111013036100_bib40","doi-asserted-by":"publisher","first-page":"e524","DOI":"10.1097\/TXD.0000000000000971","article-title":"The use of GLP1R agonists for the treatment of type 2 diabetes in kidney transplant recipients","volume":"6","author":"Kukla","year":"2020","journal-title":"Transplant Direct"},{"key":"2026033111013036100_bib41","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s13300-020-00786-1","article-title":"A retrospective study of glucagon-like peptide 1 receptor agonists for the management of diabetes after transplantation","volume":"11","author":"Thangavelu","year":"2020","journal-title":"Diabetes Ther"},{"key":"2026033111013036100_bib42","doi-asserted-by":"publisher","first-page":"948","DOI":"10.4093\/dmj.2020.0180","article-title":"Dulaglutide as an effective replacement for prandial insulin in kidney transplant recipients with type 2 diabetes mellitus: a retrospective review","volume":"45","author":"Kim","year":"2021","journal-title":"Diabetes Metab J"},{"key":"2026033111013036100_bib43","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1016\/j.transproceed.2021.08.042","article-title":"Institutional experience with new antidiabetic drugs in kidney transplant","volume":"53","author":"Yugueros Gonz\u00e1lez","year":"2021","journal-title":"Transplant Proc"},{"key":"2026033111013036100_bib44","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/15269248221122867","article-title":"Single-center evaluation of safety & efficacy of glucagon-like peptide-1 receptor agonists in solid organ transplantation","volume":"32","author":"Sweiss","year":"2022","journal-title":"Prog Transpl"},{"key":"2026033111013036100_bib45","doi-asserted-by":"publisher","first-page":"e14633","DOI":"10.1111\/ctr.14633","article-title":"Effectiveness and safety of glucagon-like peptide-1 receptor agonist in a cohort of kidney transplant recipients","volume":"36","author":"Vigara","year":"2022","journal-title":"Clin Transplant"},{"key":"2026033111013036100_bib46","doi-asserted-by":"publisher","first-page":"e15144","DOI":"10.1111\/ctr.15144","article-title":"Sodium-glucose co-transporter 2 inhibitors & glucagon-like peptide-1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients","volume":"37","author":"Mahmoud","year":"2023","journal-title":"Clin Transplant"},{"key":"2026033111013036100_bib47","doi-asserted-by":"publisher","first-page":"e15057","DOI":"10.1111\/dme.15057","article-title":"Glucagon-like peptide-1 receptor analogues in renal transplant recipients with diabetes: medium term follow of patients from a single UK centre","volume":"40","author":"Mallik","year":"2023","journal-title":"Diabet Med"},{"key":"2026033111013036100_bib48","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1210\/clinem\/dgad177","article-title":"Possible advantage of glucagon-like peptide 1 receptor agonists for kidney transplant recipients with type 2 diabetes","volume":"108","author":"Sato","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026033111013036100_bib49","first-page":"100343","article-title":"Safety and efficacy of semaglutide in post kidney transplant patients with type 2 diabetes or post-transplant diabetes","volume":"36","author":"Mahzari","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"key":"2026033111013036100_bib50","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.nefroe.2024.11.007","article-title":"Use of glucagon-like peptide type 1 receptor agonists in kidney transplant recipients","volume":"44","author":"Vigara","year":"2024","journal-title":"Nefrolog\u00eda (Engl Ed)"},{"key":"2026033111013036100_bib51","doi-asserted-by":"crossref","first-page":"101624","DOI":"10.1016\/j.diabet.2025.101624","article-title":"Glucagon-like peptide 1 receptor agonists and renal outcomes in kidney transplant recipients with diabetes mellitus","volume":"51","author":"Diker Cohen","year":"2025","journal-title":"Diabetes Metab"},{"key":"2026033111013036100_bib52","doi-asserted-by":"publisher","first-page":"848","DOI":"10.34067\/KID.0000000706","article-title":"Safety and efficacy of liraglutide and semaglutide in kidney transplant recipients","volume":"6","author":"Kahwaji","year":"2025","journal-title":"Kidney360"},{"key":"2026033111013036100_bib53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12933-025-02649-0","article-title":"Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients","volume":"24","author":"Lin","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"2026033111013036100_bib54","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.eprac.2025.02.020","article-title":"Benefits of glucagon-like peptide-1 receptor agonists after kidney transplantation","volume":"31","author":"Sahi","year":"2025","journal-title":"Endocr Pract"},{"key":"2026033111013036100_bib55","doi-asserted-by":"publisher","first-page":"e70144","DOI":"10.1111\/ctr.70144","article-title":"Efficacy, tolerability, and safety of glucagon-like peptide 1 receptor agonists (GLP1-RA) in kidney transplant recipients with diabetes","volume":"39","author":"Zelada","year":"2025","journal-title":"Clin Transplant"},{"key":"2026033111013036100_bib56","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists in kidney transplantation: a systematic review and meta-analysis","author":"Lee","year":"2025","journal-title":"Transplantation"},{"key":"2026033111013036100_bib57","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.numecd.2023.03.023","article-title":"Glucagon-like peptide 1 receptor agonists in end-staged kidney disease and kidney transplantation: a narrative review","volume":"33","author":"Clemens","year":"2023","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026033111013036100_bib58","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.2215\/CJN.0000000750","article-title":"GLP-1 receptor agonist outcomes, safety, and body mass index change in a national cohort of patients on dialysis","volume":"20","author":"Orandi","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026033111013036100_bib59","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/oby.23195","article-title":"Obesity as an isolated contraindication to kidney transplantation in the end-stage renal disease population: a cohort study","volume":"29","author":"Orandi","year":"2021","journal-title":"Obesity (Silver Spring)"},{"key":"2026033111013036100_bib60","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/j.ajt.2025.05.033","article-title":"Practices in the management of kidney transplant candidates and recipients with obesity: a survey of United States transplant programs","volume":"25","author":"Puttarajappa","year":"2025","journal-title":"Am J Transplant"},{"issue":"Suppl 4","key":"2026033111013036100_bib61","doi-asserted-by":"crossref","first-page":"iv99","DOI":"10.1093\/ndt\/gft193","article-title":"Obesity and nephrology: results of a knowledge and practice pattern survey","volume":"28","author":"Stenvinkel","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2026033111013036100_bib62","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1177\/19322968241231565","article-title":"Should we stop glucagon-like peptide-1 receptor agonists before surgical or endoscopic procedures? Balancing limited evidence with clinical judgment","volume":"19","author":"Umpierrez","year":"2025","journal-title":"J Diabetes Sci Technol"},{"key":"2026033111013036100_bib63","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bja.2025.04.001","article-title":"Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement","volume":"135","author":"Oprea","year":"2025","journal-title":"Br J Anaesth"},{"key":"2026033111013036100_bib64","volume-title":"ASA consensus-based guidance on preoperative management of patients on glucagon-like peptide-1 receptor agonists","author":"American Society of Anesthesiologists","year":"2023"},{"key":"2026033111013036100_bib65","volume-title":"Saxenda (liraglutide) [package insert]","year":"2020"},{"key":"2026033111013036100_bib66","volume-title":"Wegovy (semaglutide) [package insert]","year":"2021"},{"issue":"Suppl 1","key":"2026033111013036100_bib67","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2337\/db24-13-PUB","article-title":"13-PUB: safety and efficacy of tirzepatide in patients with solid-organ transplant","volume":"73","author":"Dowlatshahi","year":"2024","journal-title":"Diabetes"},{"key":"2026033111013036100_bib68","doi-asserted-by":"publisher","first-page":"e170671","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"key":"2026033111013036100_bib69","doi-asserted-by":"publisher","first-page":"e0222169","DOI":"10.1371\/journal.pone.0222169","article-title":"Acute pancreatitis risk after kidney transplantation: propensity score matching analysis of a national cohort","volume":"14","author":"Chuang","year":"2019","journal-title":"PLoS One"},{"key":"2026033111013036100_bib70","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2026033111013036100_bib71","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"2026033111013036100_bib72","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1056\/NEJM198408093110604","article-title":"Blood glucose control and the evolution of diabetic retinopathy and albuminuria","volume":"311","author":"Kroc Collaborative Study Group","year":"1984","journal-title":"N Engl J Med"},{"key":"2026033111013036100_bib73","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/dom.14347","article-title":"Liraglutide hospital discharge trial: a randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge","volume":"23","author":"Pasquel","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2026033111013036100_bib74","doi-asserted-by":"publisher","first-page":"e70281","DOI":"10.1111\/ctr.70281","article-title":"Pre- and post-kidney transplant abdominal computed tomography-based muscle measurements and post-KT outcomes","volume":"39","author":"Liu","year":"2025","journal-title":"Clin Transplant"},{"key":"2026033111013036100_bib75","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.transproceed.2011.12.010","article-title":"Percentages of water, muscle, and bone decrease and lipid increases in early period after successful kidney transplantation: a body composition analysis","volume":"44","author":"Harada","year":"2012","journal-title":"Transplant Proc"},{"key":"2026033111013036100_bib76","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.2337\/dc25-0690","article-title":"Gradual titration of semaglutide results in better treatment adherence and fewer adverse events: a randomized controlled open-label pilot study examining a 16-week flexible titration regimen versus label-recommended 8-week semaglutide titration regimen","volume":"48","author":"Eldor","year":"2025","journal-title":"Diabetes Care"},{"key":"2026033111013036100_bib77","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am J Clin Nutr"},{"key":"2026033111013036100_bib78","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1093\/ndt\/gfae024","article-title":"How to assess kidney outcomes in obese people with substantial weight loss: the case of GLP1- and dual-receptor agonists","volume":"39","author":"Rothberg","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026033111013036100_bib79","first-page":"860","article-title":"Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes","volume":"30","author":"Gleason","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"2026033111013036100_bib80","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1016\/j.transproceed.2010.08.027","article-title":"Preferential adherence to immunosuppressive over nonimmunosuppressive medications in kidney transplant recipients","volume":"42","author":"Terebelo","year":"2010","journal-title":"Transplant Proc"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf199\/64443280\/gfaf199.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/4\/625\/64443280\/gfaf199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/4\/625\/64443280\/gfaf199.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:01:40Z","timestamp":1774969300000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/4\/625\/8268887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":80,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,9,30]]},"published-print":{"date-parts":[[2026,3,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf199","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,9,30]]}}}